URAMIN, a polysulfonated naphthylurea originally used for treatment of African trypanosomiasis k.Jr and onchocerciasis, 16 has been shown to bind to a wide variety of polypeptide growth factors such as platelet-derived growth factor (PDGF), 11,33 epidermal growth factor (EGF), 4 and basic fibroblast growth factor (FGF)? This compound also has antiproliferative effects on lymphoid cells 26 as well as on human colon cancer cells. 7 Based on these observations, suramin has recently been entered into clinical trials for treatment of a variety of human cancers, including metastatic adrenal cancers 15 and hormone-refractory adenocarcinomas of the prostate gland. 13 A preliminary evaluation revealed that suramin was potentially useful as an anticancer drug, although there are adverse side effects. 16 Suramin has also been shown to interfere with the binding of growth factors to glioma cell lines 32 and to inhibit cell proliferation in vitro. 6, 16 '32 The potential effects of the drug on the growth of nonglial human brain tumors were given less attention. Several polypeptide growth factors seem to play a role in autocrine or paracrine growth mechanisms of certain brain tumors, including meningioma, 12,28,31 a nonglial brain tumor originating from mesenchymal tissues in the central nervous system. Insulin-like growth factor (IGF)-I is a candidate for such an autocrine regulator in human meningioma cells. 9, 12 We investigated the effect of suramin on IGF-I binding to surgically excised human meningioma tissue and on proliferation of cultured meningioma cells in vitro.
Materials and Methods

Tumor Specimens and Materials
Fresh surgically excised human meningioma specimens obtained from 8 patients (Table 1) were imme- * Consecutive sections were incubated with 50 pM tzsI-insulin-like growth factor (IGF)-I and increasing concentrations of unlabeled IGF-I (10-t2-10 -7 M), insulin (10 -~~ M), or suramin (10 -6-10 -2 M), as described in the Materials and Methods section, ICs~ = concentration that inhibits one-half of the specific binding.
diately placed in liquid nitrogen and stored at -80~ for less than 1 month. Sections 20/xm thick were cut in a eryostat at -20~ thaw-mounted on gelatin-coated glass slides, and dried overnight in a desiccator at 4~ while under vacuum. 12 Suramin, the hexasodium salt of 8,8'-{carbonyl-bis[imino-3,1-phenylenecarbamylimino(4-methyl-2,1-phenylene)carbonyl-imino]}bis-l,3,5-naphthalenetrisulfonic acid (molecular weighI 1429.21 D), was used in this study. Recombinant hurfian IGF-I, recombinant human insulin, and (3-[tzsI]iodotyrosyl) IGF-I (natural sequence) were also used.
Quantitative Receptor Autoradiography
Sections were labeled in vitro with lzsI-IGF-I (specific activity 2000 Ci/mmol), using experimentally determined incubation parameters. Each section was preincubated for 15 minutes at 22~ in 25 mM Tris-HC1 buffer (pH 7.5) containing 10 mM MgC12, bacitracin (1 mg/ml), and 0.1% protease-free bovine serum albumin (BSA), followed by incubation for 120 minutes (various periods of incubation time were used for association or dissociation experiments) in fresh buffer containing 50 pM 125I-IGF-I in the presence of increasing concentrations of unlabeled IGF-I (10 -~2 to 10 -7 M), insulin (10 -I~ to 10 -3 M), or suramin (10 -6 to 10 -2 M). After incubation, the slides were rinsed three times, for 1 minute each, in 25 mM fresh ice-cold Tris-HCl buffer (pH 7.4) followed by a dip in ice-cold distilled water; the sections were then air-dried. Nonspecific binding was determined in the presence of 0.1 ~M unlabeled IGF-I. 18 To examine the effect of suramin on dissociation of ~25I-IGF-I previously bound to the tumor tissue, the sections were incubated with 50 pM 125I-IGF-I for 120 minutes (association experiment) prior to the addition of 10 -3 M suramin or 10 -7 M unlabeled IGF-I to the buffer. This was followed by incubation for various periods up to 120 minutes (dissociation experiment).
To examine the underlying mechanism mediating the action of suramin, the following experiments were performed. After preincubation for 120 minutes in the absence or presence of 10 -3 M suramin or 10 -7 M unlabeled IGF-I, the sections were rinsed as above, then incubated with 50 pM 1251-IGF-I for an additional 120 minutes at various intervals, in association with the experiments described above.
The dry-labeled sections were exposed to a radioluminographic imaging plate coated with fine photostimulable phosphor crystals (BaFbr:Eu + +, Type BAS-III) 1 with calibrated t25I-labeled standards 20 ~m thick. The autoradiograms obtained were analyzed using the radieluminographic imaging-plate system. *t The values for photostimulated luminescence obtained directly from the imaging plates by the computerized scanning system were converted to the bound radioactivity of the section, and the results were expressed as the mean _+ standard error of the mean (SEM) in fmol/mg, based on a comparison with standard curves for sets of standards run on each autoradiogram, z5 The 50% inhibiting concentration (ICs0) values were calculated by computer.t 29 To obtain autoradiograms of a higher resolution, the dry-labeled sections were apposed against 3H-Hyperfilm in x-ray cassettes and the films were developed with a D19 Kodak developer for 4 minutes at 4~
Culture of Human Meningioma Cells"
Immediately after the removal of tumor from four patients (Cases 6, 7, 9, and 10), the specimens were minced into 1-sq mm pieces and incubated in 0.125% trypsin and 0.02% ethylenediamine tetra-acetic acid (EDTA) solution for 15 minutes at 37~ Trypsin activity was inhibited by adding Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). After centrifugation at 1500 G, the cell pellet was resuspended in complete medium (DMEM supplemented with 10% FBS) and the cells were mechanically dispersed. Cells were seeded in 75-sq cm tissue culture flasks and cultured at 37~ in 5% CO2/ 95% air with 100% humidity until subconfluence occurred at 1 week. lz
3H-Thymidine Incorporation Studies
To test the effect of suramin on deoxyribonucleic acid (DNA) synthesis induced by IGF-I in cultured human meningioma cells (from Cases 7, 9, and 10), 3H-thymidine incorporation studies were performed using a modification of the method described by Russell, et a1.,24 and described by us elsewhere. 12 The cultured meningioma cells, after a single passage, were treated with 0.1% trypsin and 0.02% EDTA solution, suspended in DMEM/Ham's F-12 medium (F-12) (1:1) containing 0.1% FBS and plated onto 24-well tissue culture plates at a density of 3 • 104 cells/well. The cells were cultured at 37~ for 48 hours, following which the medium was changed to serum-free DMEM/F-12 (1:1) and the preparation was incubated for another 48 hours. The cultures were then incubated with increasing concentrations of IGF-I (10 -11 to 10 -8 M) or suramin (10 -6 to 10 -3 M), with or without 10 -s IGF-I, or in the presence of 5% FBS, after being washed with fresh DMEM/F-12 (1:1). The control cultures were incubated with DMEM/F-12 (1:1) containing 0.1% BSA. After incubation for 24 hours, 3H-methyl thymidine (0.5/zCi/well) was added to the cultures and incubation was continued for another 4 hours at 37~ The reaction was halted by aspiration of the solution and washing the cells three times with ice-cold phosphate-buffered saline. The cultures were then incubated with 5% trichloroacetic acid (TCA) at 4~ for 20 minutes. The cultures were washed with fresh 5% TCA, after which they were solubilized in 1% sodium dodecyl sulfate. The resultant solution was added to 10 ml of complete counting cocktail, and the radioactivity of 3H-thymidine incorporated into DNA was determined using a scintillation counter. Results were analyzed by unpaired t-test; a p value of less than 0.05 was considered statistically significant.
Growth Studies
To investigate the possible action of suramin on the proliferation of meningioma cells, we counted the number of viable cells during exposure of the cultured meningioma cells (Case 6) to increasing concentrations (10 -6 to 10 -4 M) of suramin for 4 days. Briefly, 2 • 104 cells were plated in 60-ram tissue culture dishes containing DMEM/F-12 (1:1) supplemented with 5% FBS. One day after plating, the cells were treated with suramin at the appropriate concentration (10 -6 to 10 -4 M), after which they were trypsinized and counted in a hemocytometer at different time intervals (0 to 4 days) in culture. Trypan blue was used as an indicator of cell viability.
Results
Localization of ~:5I-IGF-I Binding Sites
The 125I-IGF-I binding sites were localized in tissue sections of all human meningiomas tested. Normal dural membrane adjacent to the tumor tissue did not express specific t25I-IGF-I binding sites. Diffuse IGF-I binding was observed in most cases (Fig. 1) . In several tumor sections, the binding was distributed heterogeneously. When compared with adjacent sections stained with hematoxylin and eosin, a higher density of 125I-IGF-I binding was found in tissue with cell-rich components rather than fibrous components. Identification of precise cell types expressing these binding sites in meningioma tissue was not feasible using our quantitative receptor autoradiography system because of limitations in resolution of the technique. 
Characterization of mI-IGF-I Binding Sites in Meningiomas
In the presence of 50 pM 125I-IGF-I, specific binding was detected in all tissue sections of the meningiomas studied and was 45 + 5 fmol/mg (mean _+ SEM of eight meningioma specimens). Nonspecific binding was less than 10% of the total binding. Table 1 ).
Effects of Suramin on mI-IGF4 Binding to Meningiomas
Suramin inhibited 125I-IGF-I binding to meningiomas in a dose-dependent manner with an ICs0 of 8.7 _ 0.5 • 10 -5 M, and the binding was eliminated in the presence of 10 -3 M suramin (Fig. 2 right and Table 1 ).
The 125I-IGF-I binding to meningiomas reached a steady-state level in 120 minutes (Fig. 3A) . The addition of 10 -3 M suramin enhanced the dissociation of 125I-IGF-I previously bound to tissue sections of meningiomas as a function of time (dissociation half-life !T~) 6.8 minutes) (Fig. 3B) .After 120 minutes, the bindmg was decreased to 20% of control values, which indicated that suramin was slightly less efficient at dis- IGF-I (10 -7 M) also dissociated I-IGF-I binding from the tumors; however, the potency was lower than that of 10 -3 M suramin (the binding was decreased to 35% of control values; T~ 13.5 minutes) (Fig. 3B) .
To determine if suramin decreased 125I-IGF-I binding to meningiomas by interacting with 125I-IGF-I itself or with the IGF-I binding sites, tissue sections were preincubated with or without suramin (10 -3 M) for 120 minutes. These sections were subsequently washed as described in the Materials and Methods section to remove suramin from the buffer remaining on the surface; 50 pM azsI-IGF-I was then added for an additional 120 minutes. After the tissue was washed with buffer, 125I-IGF-I binding was not significantly decreased when compared to findings in the control tissue. In contrast, when unlabeled IGF-I (10 -7 M) was placed in the preincubation solution for 120 minutes prior to washing, the subsequent association of 125I-IGF-I binding was significantly inhibited (Fig. 4) .
Effect of Suramin on IGF-I-Induced DNA Synthesis in Meningioma Cells
Incubation of meningioma cells from Case 7 with increasing concentrations of IGF-I (10 -al to 10 -8 M) for 24 hours induced a marked elevation of DNA synthesis in a concentration-dependent manner, with an approximate 50% effective concentration (EC50) of 1.3 • 10 -1~ M. Maximum stimulation (about 220% above the basal level) was observed in the presence of 10 -9 to 10 -8 M IGF-I (Fig. 5) .
Suramin potently inhibited the IGF-I-induced incorporation of 3H-thymidine into the cells and 10 -3 M surarain totally blocked DNA synthesis in the cells (estimated IC50 4.6 _+ 1.4 • 10 -5 M) (Fig. 6A and Table  2 ). It is interesting to note that, in the presence of 10 -5 M suramin, the IGF-I-induced DNA synthesis was slightly but significantly potentiated (about 15% above the basal level, p < 0.05) (Fig. 6A) . Similar inhibitory effects of suramin were observed on DNA synthesis in meningioma cells in the serum-free culture system (Fig. 6B ) and in the presence of 5% FBS (Fig. 6C and Table 2 
Effect of Suramin on Proliferation of Meningioma Cells
For doses of up to 10 -4 M suramin, meningioma cells from Case 6 survived for at least 4 days without major cytotoxic effects. The proliferation of the cells was reduced by 10%, 20%, and 50% of the control culture for suramin concentrations of 10 -6, 10 -5, and 10 -4 M, respectively. A concentration of 10 -4 M completely inhibited proliferation of meningioma cells for up to 3 days after suramin was added. It is interesting that, in the presence of 10 -5 M suramin, cell proliferation was transiently activated after only 24 hours in culture. The control was defined as the cell number cultured in DMEM/F-12 (1:1) supplemented with 5% FBS (Fig. 7) .
Discussion
This report appears to be the first with evidence of the inhibitory effects of suramin on 1z~I-IGF-I binding to surgically excised human meningiomas and on IGF-I-induced proliferation of cultured meningioma cells. The IC50 (about 0.1 raM) of IGF-I binding obtained was comparable to reported values for inhibition of IGF-I binding to human osteosarcoma cells 23 or colon cancer cells? The dissociation of IGF-I from menin~oma tissue by suramin is in agreement with recent reports on the binding of other growth factors such as PDGF H and interleukin-22~ to their cell surface receptors. Since washing procedures after preincubation with suramin failed to interfere with IGF-I binding to meningiornas, it seems most likely that suramin binds to IGF-I itself, rather than the receptor. This theory is supported by the observation that preincubation with unlabeled IGF-I prior to washing prevented IGF-I binding to meningiomas, probably by occupation of the IGF-I receptor in meningioma tissue. However, the possibility cannot be ruled out that suramin binds to the IGF-I receptor with a very low affinity and washing displaces much of the suramin from the binding sites.
Inhibition of IGF-I binding to receptors may not be a single mechanism of suramin, because the drug also prevented DNA synthesis in meningioma cells in complete growth medium. This is not due to any nonspecific cytotoxity of suramin, since growth curves of suramin-treated meningioma cells indicated the cytostatic nature of antiproliferative effects of the drug. A recent report revealed that meningioma cells in culture medium produce IGF-I, 9 and IGF-I may function as an autocrine growth factor in meningiomas. 9,~2 Furthermore, other growth factors such as PDGF, EGE or basic FGF have also been presumed to act as autocrine or paracrine growth regulators for meningioma cells in vitro, jz2s, 31 Since suramin has been shown to bind to various growth factors including PDGE 11 EGF, 4 and basic FGE 4 the possibility should be considered that suramin may inhibit proliferation of meningioma cells by blocking these multiautocrine loops. In addition, sur~min is known to inactivate growth-related en- inhibiting effect of suramin on meningioma cells is due mainly to prevention of binding of growth factors, to inhibition of intracellular enzymes, or to both remains to be elucidated.
Little is known of the mechanism of action between suramin-bound IGF-I and the IGF-I receptor. It has been suggested that suramin inhibits the binding either by occluding the receptor-binding region of the growth factor molecule or by inducing a conformational change in the molecular structure, which is necessary for interaction with the binding domain of the receptor. 19 Since the growth factors inhibited by suramin are heparin-binding proteins and suramin itself is a polyanionic compound, it seems likely that the interaction of suramin with these growth factors involves polyanion binding sites. A major effect of suramin is the microaggregation of growth factors, including acidic FGF, basic FGF, and PDGF, but not IGF-I. 19 In addition, there is evidence for a suramin-induced conformational change in IGF-I. 19 These observations suggest that suramin binds to IGF-I at its polyanion binding site and, after inducing conformational changes of the receptor recognition molecule, suramin prevents the binding of IGF-I to cell surface receptors in meningioma tissue.
The presence of IGF-I binding proteins in meningiomas has been reported. 3~ In the present study, the precise nature of J251-IGF-I binding sites could not bc determined because the molecular weight of the binding sites was not examined. The binding profile demonstrated in this report suggests the predominant expression of the type 1 IGF receptor in meningioma tissue, since insulin has been shown to compete poorly for the type 2 IGF receptor and for the IGF-binding proteins; 27 however, the existence of a small number of the binding proteins or type II receptors would need to be excluded.
Suramin is now being examined in clinical trials for the treatment of human cancers refractory to conventional modalities of therapy, including adrenocortical carcinoma, ~5 lymphoma] 4 prostatic carcinoma, 13 and renal cell carcinoma. 2~ Preliminary reports reveal that the therapeutic efficacy of suramin depends on the type of tumor and/or individual cases, ~6,2j but nothing is known of the antineoplastic effect of this drug in the treatment of brain tumors. Since suramin poorly penetrates the blood-brain barrier, 16 clinical use of the drug for intraparenchymal lesions in the brain seems restricted. Meningiomas have no blood-brain barrier, 17 and the concentration of suramin required to inhibit cell growth of meningiomas (10 -4 M or 150/xg/ml) is clinically achievable by intravenous injection? 6 Reported side effects of suramin, such as adrenal toxicity or neurotoxicity, could be reduced by the administration of a corticosteroid, ~6 by monitoring the plasma level of the drug, 16 or by using newly developed analogs of suramin with reduced toxicity. 2 It is interesting to note that a lower concentration (10 -5 M) of suramin slightly stimulated IGF-I-induced DNA synthesis in cultured meningioma cells. The proliferation of meningioma cells was also transiently stimulated 24 hours after the addition of 10 -s M surarain. The stimulatory effect (up to 200% of the control level) of low suramin concentrations (10 -5 to 10 -4 M) on the proliferation of certain human breast cancer cells has been demonstrated in the presence of complete growth medium, s In contrast, suramin-induced stimulation of DNA synthesis in meningioma cells did not exceed the control level when cultured in complete growth medium. These observations indicate that the pleiotropic effect of suramin on cell growth probably depends on the environment and/or the nature of the cell, and that the stimulation potential of the drug on meningioma cells may be much less than that of breast cancer cells, especially under physiological conditions. In this regard, the untoward nature of the drug is not likely to be a serious problem for the treatment of meningiomas. The mechanism or biological significance of the pleiotropic effect of suramin is currently unknown.
Conclusions
Our results show that suramin potently inhibits proliferation of cultured meningioma cells in vitro, at least partially by interacting with IGF-I, and that the drug also prevents IGF-I binding to surgically excised human meningiomas. Suramin may be useful as an antineoplastic agent as an alternative or adjuvant therapy K. Tsutsumi, et al. for patients with meningiomas that cannot be completely excised.
